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Invasive lobular carcinoma (ILC) is an aggressive
breast cancer subtypewith poor response to chemo-
therapy. Besides loss of E-cadherin, a hallmark of
ILC, genetic inactivation of PTEN is frequently
observed in patients. Through concomitant Cre-
mediated inactivation of E-cadherin and PTEN in
mammary epithelium, we generated a mouse model
of classical ILC (CLC), the main histological ILC
subtype. While loss of E-cadherin induced cell
dissemination and apoptosis, additional PTEN inac-
tivation promoted cell survival and rapid formation
of invasive mammary tumors that recapitulate the
histological and molecular features, estrogen recep-
tor (ER) status, growth kinetics, metastatic behavior,
and tumor microenvironment of human CLC. Com-
bined inactivation of E-cadherin and PTEN is
sufficient to cause CLC development. These CLCs
showed significant tumor regression upon BEZ235-
mediated inhibition of PI3K signaling. In summary,
this mouse model provides important insights into
CLC development and suggests inhibition of phos-
phatidylinositol 3-kinase (PI3K) signaling as a poten-
tial therapeutic strategy for targeting CLC.INTRODUCTION
Invasive lobular carcinoma (ILC) is the second most common
subtype of breast cancer, comprising 8%–14% of all breast
cancer cases (Li et al., 2003; Pestalozzi et al., 2008). ILC is histo-
logically characterized by single-cell files of tumor cells in a
fibrous stroma. Due to its invasive growth behavior, this tumor
type does not immediately form a defined tumor mass and,Cell Re
This is an open access article under the CC BY-Ntherefore, is difficult to detect by physical examination or
mammography (Houssami et al., 2003). Despite being classified
as a histologic low-grade tumor type with a low-to-intermediate
mitotic index, the infiltrating nature of ILC complicates surgical
removal. Moreover, ILCs typically respond poorly to classical re-
gimes of chemotherapy. To improve treatment options, more
insight into ILC development is required.
On the molecular level, ILC is characterized by loss of the
cell-adhesion protein E-cadherin (Moll et al., 1993), an event
that has been shown to drive tumor invasion. Nevertheless, so-
matic inactivation of E-cadherin in mouse mammary epithelium
does not induce spontaneous mammary tumor development
(Boussadia et al., 2002; Derksen et al., 2006), indicating that
additional (epi)genetic lesions are required for ILC formation.
Activation of the phosphatidylinositol 3-kinase (PI3K) pathway,
as displayed by either activating PIK3CA mutations or homozy-
gous deletions or inactivating mutations in PTEN, is frequently
observed in ILC (Buttitta et al., 2006; Ciriello et al., 2015; Michaut
et al., 2016; Michelucci et al., 2009). PI3K signaling controls
multiple cellular processes, such as cell proliferation, survival,
and migration, by the conversion of phosphatidylinositol 4,5-bi-
sphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate
(PIP3), driving activation of downstream targets such as AKT.
To test whether constitutive activation of PI3K signaling can,
indeed, drive the formation of ILC, we generatedmice withmam-
mary-specific Cre-conditional inactivation of E-cadherin and
PTEN. We found that combined loss of both E-cadherin and
PTEN in mouse mammary epithelial cells induces mouse mam-
mary tumors that closely resemble classical invasive lobular
carcinoma (CLC), the main subtype of human ILC.
RESULTS
Inactivation of E-Cadherin and PTEN In Vitro Alters
Growth and Invasion of Mammary Epithelium
To study the direct consequence of inactivation of E-cadherin
(encoded by the Cdh1 gene) and PTEN in primary mammaryports 16, 2087–2101, August 23, 2016 ª 2016 The Author(s). 2087
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Inactivation of E-Cadherin and PTEN Alters Mammary Epithelial Morphology and Growth In Vitro
(A) Western blot analyses of E-cadherin, PTEN, and p-AKT(Ser473)/AKT protein expression of untransduced and AdCre-transduced Cdh1F/F, PtenF/F, and
Cdh1F/F;PtenF/F mammary organoids.
(B) Representative bright-field images of untransduced and AdCre-transduced Cdh1F/F, PtenF/F, and Cdh1F/F;PtenF/Fmammary organoids at day 21 of organoid
culture. The dashed circle depicts the surface size of AdCre-transduced Cdh1F/F organoids. Scale bar, 50 mm.
(legend continued on next page)
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epithelial cells, we generatedmammary organoids fromCdh1F/F;
PtenF/Fmice (Derksen et al., 2006; Ma et al., 2005). In vitro trans-
duction of organoids using a Cre-recombinase-encoding adeno-
virus (AdCre) allowed us to test the direct effects of E-cadherin
and PTEN loss in mammary epithelium. To confirm efficient
AdCre-mediated recombination in vitro, we used organoids
from mTmG reporter mice that express tandem dimer Tomato
(tdT) prior to recombination and GFP after Cre-mediated exci-
sion of tdT (Muzumdar et al., 2007). AdCre transduction of
mTmG organoids induced loss of tdT and expression of GFP in
nearly all cells (Figure S1A). Importantly, the phenotype of
AdCre-transduced mTmG organoids appeared unaltered as
compared to non-transduced organoids from the same mouse,
indicating that organoid growth rate and phenotype are not
affected by AdCre transduction (Figure S1A). This strategy
was, therefore, applied to inactivate E-cadherin and/or PTEN in
Cdh1F/F, PtenF/F, and Cdh1F/F;PtenF/F organoids, respectively.
All non-transduced organoids displayed similar-sized cyst-like
structures after 7 days of culture (Figure S1B). The inactivation
of E-cadherin alteredmammary organoid phenotype by inducing
discohesive cellular structures surrounding the organoid cores,
while the inactivation of PTEN resulted in enlarged smooth-
edged organoids (Figure S1B). Concurrent inactivation of E-cad-
herin and PTEN revealed a combined phenotype of Cdh1D/D and
PtenD/D organoids, as Cdh1D/D;PtenD/D organoids were both
enlarged and showed discohesive cellular structures (Fig-
ure S1B). Efficient recombination was confirmed by western
blotting and PCR, showing strong reduction of E-cadherin and/
or PTEN protein expression and deletion of the Cdh1F and PtenF
alleles, respectively (Figures 1A and S1C). In addition, AdCre-
transduced PtenF/F and Cdh1F/F;PtenF/F organoids showed a
strong induction of AKT phosphorylation, indicating activation
of PI3K signaling due to PTEN loss (Figure 1A).
To study the long-term consequences of E-cadherin and/or
PTEN loss in mammary epithelial cells, we monitored organoid
development over a period of 21 days. Non-transduced organo-
ids from each genotype decreased similarly in size and were
hardly detectable after 21 days of culture (Figure 1B). The size
of Cdh1D/D organoids remained stable, while the size of PtenD/D
and Cdh1D/D;PtenD/D organoids continued to increase (Figures
1B and 1C). Again, the margins of both Cdh1D/D and
Cdh1D/D;PtenD/D organoids showed discohesive cellular struc-
tures (Figure 1B).
To examine why growth kinetics differed between Cdh1D/D
and Cdh1D/D;PtenD/D organoids, we analyzed cell proliferation
and apoptosis by immunofluorescence (IF) with antibodies
against Ki-67 and cleaved caspase-3 (CC3), respectively.
Cdh1D/D organoids showed a balanced number of cells in prolif-
eration or apoptosis, which might explain their sustained size(C) Average measurements of surface size (n = 10 per genotype) of untransduce
days 7, 14, and 21 of organoid culture.
(D) Expression of Ki67 and CC3 measured by whole-mount immunostaining of Ad
50 mm.
(E) Quantification of the fraction of Ki67- and CC3-positive cells over the total ce
Cdh1F/F;PtenF/F (n = 10 per genotype).
(F) Representative bright-field images of a Cdh1F/F;PtenF/F organoid displaying in
Scale bars, 25 mm.over time (Figures 1D and 1E). Consistent with a survival role
for the PI3K signaling pathway, both PtenD/D and Cdh1D/D;
PtenD/D organoids showed almost no apoptotic cells (Figure 1E),
resulting in an increase in organoid size over time (Figures 1B
and 1C).
In contrast to PtenD/D organoids, Cdh1D/D;PtenD/D organoids
displayed an invasive response upon renewal of the cell culture
medium (Figures 1F and S1D). These invasive cellular strands
displayed single files of cells, indicating an increased invasive
potential ofCdh1D/D;PtenD/Dmammary epithelium upon stimula-
tion by growth factors and/or chemoattractants in the culture
medium.
Together, these observations suggest that PI3K pathway acti-
vation through the disruption of PTEN can rescue apoptosis
induced by E-cadherin loss in mammary epithelial organoids, re-
sulting in invasive and proliferative behavior in vitro.
Inactivation of E-Cadherin and PTEN in Mammary
Epithelium In Vivo Induces Rapid Formation of
Hyperplastic and Infiltrative Lesions
To study the consequences of E-cadherin and PTEN loss in vivo,
we generatedWcre;Cdh1F/F;PtenF/F femalemice, in whichmam-
mary-epithelium-specific inactivation of E-cadherin and PTEN is
induced by whey acidic protein (WAP) gene promoter-driven Cre
recombinase (Wcre) (Derksen et al., 2006). We also generated
Wcre;Cdh1F/F andWcre;PtenF/F female mice to study the effects
of E-cadherin or PTEN loss alone. Since Wcre activity is first
detectable in the fourth week of mammary gland development
(data not shown), we analyzed the consequences of somatic
inactivation of E-cadherin and/or PTEN during mammary gland
development. Histological analysis and immunohistochemistry
(IHC) for cytokeratin 8 (CK8; marking luminal mammary epithelial
cells) indicated inactivation of E-cadherin to cause hyperplastic
and dysplastic ducts, as well as a marked accumulation of
dissociated mammary epithelial cells in the lumen of mammary
epithelium from 6-week-old Wcre;Cdh1F/F mice (Figure 2A).
Inactivation of PTEN alone did not reveal distinct alterations in
mammary epithelial composition in Wcre;PtenF/F (Figure 2A). In
contrast, mammary epithelium from 6-week-old Wcre;Cdh1F/F;
PtenF/F mice displayed multifocal neoplastic lesions infiltrating
the surrounding stroma (Figure 2A). Analysis of over 20 nullipa-
rous Wcre;Cdh1F/F;PtenF/F mice confirmed a robust synergy
between loss of E-cadherin and PTEN in driving formation of
these mammary epithelial lesions, as all mice displayed
neoplastic lesions at 6 weeks of age. The infiltration pattern of
these neoplastic lesions showed strong resemblance with the
characteristic trabecular and discohesive growth pattern of
tumor cells in human CLC. We confirmedWcre-mediated inacti-
vation of E-cadherin and/or PTEN in luminal epithelial cells by IFd and AdCre-transduced Cdh1F/F, PtenF/F, and Cdh1F/F;PtenF/F organoids at
Cre-transduced Cdh1F/F, PtenF/F, and Cdh1F/F;PtenF/F organoids. Scale bars,
ll number (determined by Hoechst) in AdCre-transduced Cdh1F/F, PtenF/F, and
vasive protrusions of single rows of cells (arrows) 1 day after medium change.
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(Figures 2B and S2A). Analysis of Wcre;Cdh1F/F glands showed
that E-cadherin-deficient cells in the lumen are CK8 positive,
indicating that these cells indeed dissociated from the luminal
epithelium (Figure S2A). This phenomenon is likely caused by
reduced junctional integrity following E-cadherin loss (Shamir
et al., 2014). Even though Wcre;PtenF/F glands did not display
neoplastic lesions within 6 weeks, we clearly observed stochas-
tic loss of PTEN in luminal epithelial cells (Figure S2A). The
neoplastic lesions observed in Wcre;Cdh1F/F;PtenF/F mammary
glands displayed discohesive CK8-marked luminal epithelial
cells that, indeed, lost E-cadherin and PTEN, whereas surround-
ing stromal cells retained PTEN expression (Figure 2B). More-
over, E-cadherin-deficient cells still expressed CK8, indicating
that these cells did not undergo epithelial-to-mesenchymal tran-
sition (EMT), as also previously observed (Derksen et al., 2006).
Since inactivation of PTEN rescued apoptosis and promoted
survival of E-cadherin-deficient mammary epithelial cells in
Cdh1D/D;PtenD/D organoids, we analyzed apoptosis by CC3 IF
staining in mammary gland sections from 6-week-old
Wcre;Cdh1F/F, Wcre;PtenF/F, and Wcre;Cdh1F/F;PtenF/F mice.
While no apoptosis was observed in Wcre;PtenF/F and
Wcre;Cdh1F/F;PtenF/F mammary glands, CK8-positive cells in
the lumen of mammary ducts in Wcre;Cdh1F/F mice displayed
CC3-marked apoptosis (Figures 2C and 2D). Compared to
Cdh1D/D organoids, Wcre;Cdh1F/F mammary glands showed
only limited numbers of CC3-marked cells, most likely due to
rapid clearance of apoptotic cells in the lumen of mammary
ducts. These data underscore the notion that the loss of PTEN
promotes survival of E-cadherin-deficient mammary epithelial
cells through inhibition of apoptosis.
To further investigate the effects of concomitant inactivation of
E-cadherin and PTEN on mammary gland development and
functionality, we analyzed mammary gland outgrowth during pu-
berty and mammary gland maturation during pregnancy in nine
Wcre;Cdh1F/F;PtenF/F mice. Whole-mount analysis of mammary
glands from 8-week-old Wcre;Cdh1F/F;PtenF/F mice showed,
beside neoplastic lesions and hyperplastic ducts, a delay in
mammary gland development, as compared to age-matched
wild-type mammary glands (Figure S2B). Impaired mammary
gland maturation was also observed during pregnancy, as
pups from five 12-week-old Wcre;Cdh1F/F;PtenF/F mice grew
poorly and died 6 days after birth, while littermates fostered
onto wild-type dams showed normal weight and survival (Fig-
ure S2C). This phenomenon is likely caused by the reduced
numbers of milk-producing glands in Wcre;Cdh1F/F;PtenF/F
mice, as compared to wild-type foster dams (Figure S2D).
Thus, both the development and maturation of Cdh1D/D;PtenD/D
mammary epithelium is strongly impaired, which is likely causedFigure 2. Inactivation of E-Cadherin and PTEN in Mammary Epithelium
(A) H&E staining and IHC of CK8 in mammary glands from 6-week-old wild-typ
150 mm.
(B) IF analysis of CK8, E-cadherin, and PTEN in mammary glands from 6-week-ol
area reveal CK8-positive neoplastic cells that are negative for of E-cadherin and
(C) IF analysis of CK8 (green) and CC3 (red) in mammary glands from 6-week-old
mammary duct. Scale bar, 20 mm.
(D) Average numbers of CC3-positive shedded cells per 500-mm2 area in ma
PtenF/F mice.by the loss of mammary epithelial integrity and formation of
multi-focal neoplasia.
Inactivation of E-Cadherin and PTEN Drives Formation
of Mammary Tumors that Closely Resemble Human CLC
To examine potential synergy between E-cadherin and PTEN
loss in mammary tumorigenesis, we monitored tumor formation,
as detected by palpation, in Wcre;PtenF/+, Wcre;PtenF/F,
Wcre;Cdh1F/F;PtenF/+, and Wcre;Cdh1F/F;PtenF/F mice. In line
with previous literature, female Wcre;PtenF/+ and Wcre;PtenF/F
mice developed heterozygous or homozygous mammary tu-
mors, with median latencies of 615 and 250 days, respectively
(Figure 3A) (Li et al., 2002). Additional inactivation of E-cadherin
significantly decreased mammary tumor latency to 109 days of
age in Wcre;Cdh1F/F;PtenF/F mice, demonstrating strong
synergy between E-cadherin and PTEN loss in mammary tumor-
igenesis (Figure 3A). Interestingly, Wcre;Cdh1F/F;PtenF/+ and
Wcre;PtenF/+ female mice showed a similar tumor-free survival,
indicating that complete loss of PTEN is required for malignant
transformation of E-cadherin-deficient mammary epithelial cells
(Figure 3A).
To analyze the mammary tumors for each genotype, mice
were sacrificed when tumors reached 225 mm2, except for
Wcre;Cdh1F/F;PtenF/F mice, which were sacrificed after a me-
dian period of 101 days after tumor detection due to cumulative
burden of multifocal tumors, abnormal locomotory behavior, or
skin ulceration (both associated with infiltrating tumor cells in
surrounding tissues) (Figure S3A). Mammary tumors from
Wcre; PtenF/+mice displayed diverse histological phenotypes,
including solid carcinomas, squamous metaplastic carcinomas,
and EMT-like tumors, whileWcre; PtenF/Fmice solely developed
squamous metaplastic carcinomas (Figures 3B and S3A), sug-
gesting that somatic PTEN loss, on its own, preferentially drives
the development of this particular tumor type.
Notably, additional inactivation of E-cadherin completely
shifted mammary tumor morphology. About half (57%) of mam-
mary tumors in Wcre;Cdh1F/F;PtenF/+ mice and nearly all (96%)
tumors in Wcre;Cdh1F/F;PtenF/F mice displayed infiltrative pat-
terns of single files of tumor cells into the surrounding stroma
(Figures 3B and 3C). IHC staining of tumor sections confirmed
the absence of E-cadherin and PTEN protein in CK8-marked
tumor cells, whereas surrounding stromal cells retained PTEN
expression (Figure 3C). Moreover, IHC staining revealed
elevated levels of phosphorylated (p)-AKT, p-4ebp1, and p-S6
in tumor cells, confirming the activation of PI3K signaling
due to loss of PTEN (Figure S3B). Given that this phenotype
comprises key characteristics of human CLC, we designated
these tumors as mouse CLC (mCLC). Interestingly, mCLCsIn Vivo Induces Rapid Formation of Neoplastic Lesions
e, Wcre;Cdh1F/F, Wcre;PtenF/F, and Wcre;Cdh1F/F;PtenF/F mice. Scale bars,
dWcre;Cdh1F/F;PtenF/Fmice. Scale bar, 20 mm. Zooms of the asterisk-marked
PTEN (indicated by arrows), flanked by PTEN-positive stromal cells.
Wcre;Cdh1F/F;PtenF/F mice. Arrows mark CC3-positive apoptotic cells in the
mmary gland sections from Wcre;Cdh1F/F, Wcre;PtenF/F and Wcre;Cdh1F/F;
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from Wcre;Cdh1F/F;PtenF/+ mice completely lost PTEN protein
expression as analyzed by IHC, indicating that ILC formation
requires complete loss of PTEN expression (Figure S3E). The
remaining mammary tumors from Wcre;Cdh1F/F;PtenF/+ mice
were classified as solid ILC, squamous metaplastic carcinomas,
or EMT-like tumors that possibly developed due to incomplete
loss of PTEN expression (Figure 3B).
Since the majority of human CLCs are estrogen receptor (ER)
positive, we analyzed ER expression in mCLCs from
Wcre;Cdh1F/F;PtenF/F mice, revealing a mean of 26% ER-posi-
tive tumor cells (Figures 3C, 3D, and S3C). In contrast, a mean
of only 0.1% ER-positive cells was observed in Brca1D/D;
Trp53D/D mouse mammary tumors, which are known to be ER
negative (Liu et al., 2007). Also, the expression of Esr1 mRNA,
encoding ERa, was found to be increased in Cdh1D/D;PtenD/D
mCLCs, as compared to Brca1D/D;Trp53D/D mouse mammary
tumors (Figure S3F). Expression of Esr1 mRNA was also
observed in FACS (fluorescence-activated cell sorting)-sorted
EpCAM (epithelial cell adhesion molecule)-positive tumor cells,
confirming the ER positivity of tumor cells in mCLC (Figures
S3C and S3F).
Based on their gene expression profiles, human CLCs are
classified as luminal-A tumors (Ciriello et al., 2015; Iorfida
et al., 2012). To assess the molecular subtype of mCLCs from
Wcre;Cdh1F/F;PtenF/F mice, hierarchical clustering of RNA-seq
data from 956 human breast cancers and 42 mouse mammary
tumors was performed using the PAM50 gene set, which allows
classification of breast tumors into luminal, basal-like, HER2-
positive and normal-like subgroups (Parker et al., 2009).
Whereas the 22 Brca1D/D;Trp53D/D mammary tumors clustered
together with human basal-like breast cancers, all 20 Cdh1D/D;
PtenD/D mCLCs were classified as luminal-A tumors, indicating
that these mouse tumors closely resemble the molecular sub-
type of human CLC (Figure 3E). In summary, the combined
loss of E-cadherin and PTEN drives a rapid onset of mCLCs
that recapitulate the morphology, ER positivity, and molecular
subtype of human CLC.
Mammary Gland Reconstitution Exposes Slow and
Linear Growth of De Novo mCLCs
HumanCLCs are typically slow-growing tumors with a low-to-in-
termediate mitotic index. Unfortunately, mCLC growth kinetics
could not be measured in Wcre;Cdh1F/F;PtenF/F mice, which
display multifocal tumor formation in all mammary glands.
To assess the growth kinetics of mCLCs, we performed mam-
mary gland reconstitutions by orthotopic transplantation of
small fragments of tumor-free mammary gland tissue fromFigure 3. Somatic Inactivation of E-Cadherin and PTEN Induces Mamm
(A) Mammary tumor-free survival plot of Wcre;PtenF/+ (n = 26), Wcre;Cdh1F/F;Pt
Latency is shown in days of age. n.s., not significant.
(B) Pie charts showing the distribution of mammary tumor phenotypes in Wcr
Wcre;Cdh1F/F;PtenF/F (n = 238) mice.
(C) Representative H&E staining and IHC of CK8, Vimentin, E-cadherin, PTEN, an
bars, 25 mm. The zoom of the asterisk-marked area reveals PTEN-negative tumo
(D) Quantification of ER-positive tumor cells detected by IHC of ER in Brca1D/D;T
(E) Unsupervised hierarchical clustering of 956 human breast cancer samples, 22
samples. Sidebars indicate tumor subtype according to PAM50 for the human b
status for all tumors.Wcre;Cdh1F/F;PtenF/F mice into cleared mammary fat pads of
wild-type mice. In 82 out of 104 reconstituted mammary glands,
a palpable tumor was detected after a median latency period of
102 days, which is similar to the median latency of 109 days in
the spontaneous mouse model (Figure 4A). Since tumor devel-
opment after mammary gland reconstitution occurred at a single
location, it allowed reliable assessment of tumor size. Up to
250 days after tumor detection, which is more than twice the
age the spontaneous mouse model reaches, a linear and slow
growth rate was observed for all 82 tumors to an average size
of only 8.6 mm2 (Figures 4B, 4C, and S4A). These linear growth
kinetics are unique for mouse tumors, which generally exhibit
exponential tumor growth, and are very comparable to the
slow growth kinetics of humanCLC. The fact that mCLCs display
constant and linear growth kinetics from the time of detection
onward suggests that no additional mutations are required for
CLC formation besides loss of E-cadherin and PTEN.
Interestingly, 17 out of 82 mCLCs showed a sudden transition
from linear to exponential growth kinetics between 8 and
21months after tumor detection (Figure 4D). These exponentially
growing tumors displayed non-CLC phenotypes, including solid
ILC and EMT-like tumors, which were also observed in a small
fraction of the spontaneous tumors from Wcre;Cdh1F/F;PtenF/F
mice (Figures 3B and S3B). The sudden and stochastic transition
from linear to exponential growth kinetics suggests the acquisi-
tion of additional mutations in these tumors over time. Indeed,
whole-exome sequencing of seven randomly selected expo-
nentially growing tumors and 14 mCLCs revealed that all ex-
ponentially growing tumors harbored mutations in at least one
cancer-related gene, while none of the mCLCs showed addi-
tional mutations (Figure 4E). Similarly, DNA copy-number varia-
tion (CNV) analysis showed that mCLCs displayed relatively
stable genomic profiles, whereas exponentially growing tumors
contained multiple DNA copy-number aberrations (Figures 4F
and S4B).
In summary, we successfully developed a mammary gland
reconstitution model for CLC, highlighting a linear growth rate
of these tumors and indicating that combined E-cadherin and
PTEN loss is sufficient and, thus, causal for CLC development.
Metastatic Spectrum of mCLCs Mimics that of
Human CLC
Human CLC is characterized by its invasive and metastatic
behavior. Similarly, mCLCs displayed tumor invasion, as de-
tected by the examination of tumor sections, revealing irregular
tumor edges with files of tumor cells invading surrounding tis-
sues such as fat, muscle, and nerves (Figures 5A and 5B). Inary Tumors that Closely Resemble Human CLC
enF/+ (n = 39), Wcre;PtenF/F (n = 23), and Wcre;Cdh1F/F;PtenF/F (n = 60) mice.
e;PtenF/+ (n = 7), Wcre;Cdh1F/F; PtenF/+ (n = 23), Wcre;PtenF/F (n = 28), and
d ER in mammary tumors from 12-week-oldWcre;Cdh1F/F;PtenF/Fmice. Scale
r cells flanked by PTEN-positive stromal cells.
rp53D/D (n = 10) and Cdh1D/D;PtenD/D (n = 14) mammary tumors.
Brca1D/D;Trp53D/Dmammary tumor samples, and 20 Cdh1D/D;PtenD/DmCLC
reast tumors, genotypes for the mouse mammary tumors, and Cdh1 mutation
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Figure 4. Mammary Gland Transplantation
Reveals Linear Growth Kinetics of mCLCs
(A)Mammary-tumor-free survival inWcre;Cdh1F/F;
PtenF/Fmice and wild-type mice transplanted with
small precancerous mammary gland fragments
from Wcre;Cdh1F/F;PtenF/F mice.
(B) Average size of tumors in mice transplanted
with precancerous Wcre;Cdh1F/F;PtenF/F mam-
mary gland fragments (n = 82).
(C) Pie chart showing distribution of tumor
phenotypes from mice transplanted with pre-
cancerous Wcre;Cdh1F/F;PtenF/F mammary gland
fragments (n = 58).
(D) A fraction (n = 17) of mice transplanted with
precancerous Wcre;Cdh1F/F;PtenF/F mammary
gland fragments showed a sudden transition from
linear to exponential growth 250–450 days after
tumor onset.
(E) Overview of oncogenic mutations identified in
exponentially growing solid ILCs and EMT tumors.
(F) Number of genomic aberrations in linear-
growing mCLCs (n = 14) or exponential-growing
solid ILCs and EMT tumors (n = 7).line with previous observations (Cheung et al., 2013), we
observed a mixture of CK8 and cytokeratin-14 (CK14) double-
positive tumor cells and CK14 single-positive tumor cells at the
invasive front (Figure S5A). We also investigated metastatic
behavior for each tumor genotype. In Wcre;PtenF/+ and Wcre;
PtenF/F mice, no microscopic metastases could be detected in
any organ, possibly due to the presence of intact adherens junc-
tions (Figure 5C). In contrast, microscopic or macroscopic me-
tastases were observed in 34% and 5% of tumor-bearing
Wcre;Cdh1F/F;PtenF/+ and Wcre;Cdh1F/F;PtenF/F mice, respec-
tively (Figure 5C). These metastases were detected at various
distant sites that are also typical for human CLC, including
lymph nodes, lungs, pleura, peritoneum, and abdominal viscera
(Figures 5C and 5D). The distribution of the primary tumor pheno-
types inmice that developedmetastases was similar to the over-
all distribution, with the majority of primary tumors displaying an
mCLC phenotype (Figures 3B and S5B). A plausible explanation
for the lower number of metastases in Wcre;Cdh1F/F;PtenF/F
mice lies in the fact that these mice were sacrificed at a relatively
young age (median, 210 days), as compared to Wcre;Cdh1F/F;2094 Cell Reports 16, 2087–2101, August 23, 2016PtenF/+ mice, which were sacrificed at a
median age of 634 days (Figure S5C).
Therefore, Wcre;Cdh1F/F;PtenF/F mice
might have been too young at the time
of sacrifice to permit detection of (slow-
growing) metastases. This notion is sup-
ported by the fact that theWcre;Cdh1F/F;
PtenF/F mice with detectable metastases
were the oldest of all mice analyzed (Fig-
ure S5D). However, no metastatic lesions
were observed in lungs from ten aged
mice that had been reconstituted with
mammary gland tissue from Wcre;
Cdh1F/F;PtenF/Fmice as described earlier
(Figure 4B). Therefore, it cannot beexcluded that the late onset of tumor formation inWcre;Cdh1F/F;
PtenF/+ mice might favor the development of distinct ILCs with
increased metastatic capacity.
Next, we used FACS analysis to search for single mCLC cells
in the circulation or in common sites of human CLC metastasis,
such as bone marrow or lungs. To facilitate the identification of
single tumor cells, we used Wcre;Cdh1F/F;PtenF/F;mTmG mice
in which GFP expression marks Wcre-mediated loss of E-cad-
herin and PTEN (Muzumdar et al., 2007). IHC staining of
mammary gland sections indeed confirmed the formation of
GFP-positive mCLCs inWcre;Cdh1F/F;PtenF/F;mTmGmice (Fig-
ure S5E). FACS analysis of primary tumor tissue from five
Wcre;Cdh1F/F;PtenF/F;mTmG mice revealed 10%–15% GFP-
positive cells, implying that the majority of cells in mCLC are
non-tumor cells (Figure 5E). As expected, FACS analysis of
blood samples revealed low numbers of circulating tumor cells
(CTCs) in all Wcre;Cdh1F/F;PtenF/F;mTmG mice analyzed, sug-
gesting that tumor cells are able to shed from the primary tumor
and intravasate into the blood circulation (Figures 5E and 5F).
Furthermore, low numbers of GFP-positive cells were detected
in bone marrow and lung tissue, indicating infiltration of dissem-
inated tumor cells into these organs (Figures 5E and 5F). The low
number of GFP-marked tumor cells might underestimate the
actual number of disseminated tumor cells, as the presence of
Tomato and GFP double-positive CTCs in the blood revealed
incomplete switching of the homozygous mTmG reporter
alleles. Nevertheless, these results show that mCLCs exhibit
an invasive and metastatic behavior that strongly resembles
that of human CLC.
Early Stromal Recruitment in CLC
Histological and FACS analysis indicated mCLCs to contain a
large proportion of non-tumor cells (Figures 3C and 5E). There-
fore, we performed a detailed histological characterization of
the tumor microenvironment of mCLCs and compared it to that
of human CLCs. Besides H&E staining, we included Masson’s
trichrome staining to visualize collagen fibers, a major compo-
nent of the extracellular matrix, and IHC stainings to detect fibro-
blasts (PDGFRb), T cells as a major component of the adaptive
immune system (CD3), andmacrophages as amajor component
of the innate immune system (F4/80 or CD68).
We analyzed both early lesions and more advanced tumors in
6-week-old and 25-week-old wild-type, Wcre;Cdh1F/F, Wcre;
PtenF/F, andWcre;Cdh1F/F;PtenF/Fmice, respectively (Figure 6A).
In 6-week-old wild-type and Wcre;PtenF/F mice (Figures 6A,
S6A, and S6B) and 25-week-old wild-type mice (data not
shown), mammary ducts were surrounded by a thin layer of
blue-colored collagen fibers and PDGFRb-positive fibroblasts,
containing few CD3-positive T cells and F4/80-positive macro-
phages. In contrast, mammary ducts of both Wcre;Cdh1F/F
andWcre;Cdh1F/F;PtenF/Fmice clearly showed an alteredmicro-
environment. In Wcre;Cdh1F/F mammary glands, a relatively
normal epithelial layer was surrounded by an thickened layer of
collagen fibers and fibroblasts, showing slightly increased
numbers of macrophages, but no notable changes in T cell
numbers (Figure 6A). Even more profound changes in the micro-
environment ofmammary ducts were observed inWcre;Cdh1F/F;
PtenF/F mice. Early lesions of 6-week-old Wcre;Cdh1F/F;PtenF/F
mice showed a clear increase in collagen and numbers of fibro-
blasts and displayed increased numbers of infiltrating macro-
phages and T cells, especially at the periphery (Figure 6A).
Similar phenotypes were observed in more advanced tumors
of 25-week-old Wcre;Cdh1F/F;PtenF/F mice, indicating that
stromal recruitment is a continuous process with preservation
of the composition (Figure 6A).
To investigate whether the stromal composition of mCLC re-
sembles that of human CLC, we analyzed breast tissue samples
from five healthy individuals and tumor tissue from 12 CLC pa-
tients. Analysis of normal breast tissue yielded similar results
as those from wild-type mice, showing little collagen and low
numbers of fibroblasts, T cells, or macrophages surrounding
mammary ducts (Figure 6B). Similar to mCLCs, human CLCs
showed abundant collagen fibers and fibroblasts, infiltrating
macrophages, and increased numbers of T cells that were
mainly located at the tumor periphery (Figure 6B). In summary,
both human CLCs and mCLCs arising in Wcre;Cdh1F/F;PtenF/F
mice are heterotypic tumors characterized by a rich stromal
compartment consisting mainly of collagen and fibroblasts.Inhibition of PI3K Signaling Has Antitumor Activity in
Wcre;Cdh1F/F;PtenF/F Mice
As previously mentioned, the PI3K signaling pathway is
frequently mutated in human ILC. In line with the role of PTEN
as a negative regulator of PI3K signaling, CLCs from our
Wcre;Cdh1F/F;PtenF/F mouse model showed activated PI3K
signaling, as evidenced by elevated levels of p-AKT and p-S6
(Figure 7A). Given that improved treatments for human CLC
are highly desirable, we asked whether the PI3K signaling
pathway might be a potential therapeutic target for CLC. To
this end, we performed a preclinical intervention study in
Wcre;Cdh1F/F;PtenF/F female mice with the dual PI3K/mTOR
(mammalian target of rapamycin) inhibitor BEZ235 (Liu et al.,
2009). Eight-week-old littermates were treated with BEZ235 or
vehicle for a period of 28 days. Target inhibition of the PI3K
signaling pathway by BEZ235 was confirmed by IHC and west-
ern blotting, showing decreased phosphorylation of both AKT
and S6 in CLCs from mice treated with BEZ235 (Figures 7A
and 7B). As expected, vehicle-treated Wcre;Cdh1F/F;PtenF/F fe-
male mice showed, at the end of treatment, more and larger le-
sions than age-matched Wcre;Cdh1F/F;PtenF/F mice did at the
start of treatment (t = 0) (Figures 7C and 7D). Significantly fewer
and smaller CLC lesions were observed in the mammary glands
of BEZ235-treated littermates compared to t = 0 and vehicle-
treated Wcre;Cdh1F/F;PtenF/F mice, indicating that this PI3K/
mTOR inhibitor strongly inhibited tumor formation in our mCLC
model (Figures 7C and 7D). Together, these findings indicate
that pharmacological inhibition of PI3K signaling may be a prom-
ising therapeutic strategy to target CLCs that harbor activating
mutations in this pathway.
DISCUSSION
In this study, we show that concomitant inactivation of E-cad-
herin and PTEN leads to rapid formation of mouse mammary tu-
mors that faithfully recapitulate the histopathology, molecular
phenotype, ER status, growth kinetics, metastatic behavior,
and tumor microenvironment of human CLC. Inactivating muta-
tions of E-cadherin and PTEN co-occur in a substantial fraction
(13%) of human ILCs (Ciriello et al., 2015). In line with this, our
data revealed potent synergism and causality between E-cad-
herin and PTEN inactivation in CLC formation. Previously, we re-
ported that inactivation of E-cadherin and P53 in mammary
epithelium results in the development of pleomorphic ILC, a rela-
tively rare subtype of ILC (Derksen et al., 2006, 2011). In contrast,
inactivation of PTEN alters the tumor outcome of E-cadherin-
deficient cells toward CLC, which is the most common subtype
of ILC (Iorfida et al., 2012). Although E-cadherin inactivation
alone is insufficient to induce tumor formation (Boussadia
et al., 2002; Derksen et al., 2006, 2011), it appears to be required
for ILC formation by dictating tumor outcome of P53- and PTEN-
deficient mammary epithelial cells toward pleomorphic ILC and
CLC, respectively. Thus, besides being recognized as a hallmark
of ILC (Zschiesche et al., 1997), E-cadherin inactivation is also
required for ILC formation.
In apparent contrast to its tumor-suppressor role, E-cadherin
inactivation limits mammary epithelial cell survival in vivo as
E-cadherin-deficient luminal epithelial cells were found toCell Reports 16, 2087–2101, August 23, 2016 2095
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accumulate in the lumen of mammary ducts and undergo
apoptosis, which ismost likely due to reduced junctional integrity
caused by E-cadherin loss (Shamir et al., 2014). Previously,
E-cadherin inactivation in the mammary gland was found to limit
the survival of alveolar cells during the onset of lactation (Bous-
sadia et al., 2002), supporting a role for E-cadherin inmaintaining
the survival of luminal mammary epithelial cells. E-cadherin-defi-
cient mammary epithelium was also unable to expand in vitro
and required concomitant inactivation of PTEN for outgrowth
and invasion. PTEN inactivation also enabled the survival of
E-cadherin-deficient mammary epithelial cells in vivo, permitting
the formation of CLC. Importantly, as tumor onset in female
Wcre;Cdh1F/F;PtenF/F mice was extremely rapid, and no addi-
tional mutations were detected in the ensuing mCLCs, the
combined inactivation of E-cadherin and PTEN appears to be
sufficient and, thus, causal for CLC formation.
PTEN is an important negative regulator of the PI3K signaling
pathway, which controls cell survival (Cully et al., 2006). It is,
therefore, likely that activation of PI3K signaling due to loss of
PTEN promotes the survival of E-cadherin-deficient mammary
epithelial cells and subsequent formation of CLC. Indeed,
mCLCs from our Wcre;Cdh1F/F;PtenF/F mouse model showed
activated PI3K signaling, as evidenced by expression of p-AKT
and p-S6. Also, human ILCs were found to show frequent activa-
tion of PI3K signaling, as evidenced by increased AKT phos-
phorylation, reduced PTEN expression, and a high incidence of
somatic mutations leading to PI3K pathway activation (Ciriello
et al., 2015). Together, these data suggest that PI3K pathway in-
hibitors might effectively target CLC. In line with this, mCLC for-
mation in female Wcre;Cdh1F/F;PtenF/F mice was significantly
decreased by treatment with the dual PI3K/mTOR inhibitor
BEZ235, indicating that the PI3K signaling pathway is an impor-
tant Achilles’ heel of CLC. At present, BEZ235 is under evalua-
tion in phase I/II clinical trials (Bendell et al., 2015), and future
studies are needed to investigate its efficacy in patients with
CLC. However, it should be noted that antitumoral efficacy of
PI3K pathway inhibitors might be reduced, in case CLCs acquire
additional activating mutations in oncoproteins, such as KRAS,
or loss-of-function mutations in tumor suppressors, such as
PTPN11/SHP2 and p53, which we identified to alter tumor
outcome and growth kinetics of mCLCs.
Other strategies to target CLC might involve targeting the tu-
mor microenvironment, which can promote growth, metastasis,
and therapy resistance of breast cancer (Boelens et al., 2014;
Giussani et al., 2015; Unsworth et al., 2014). Furthermore, the
massive deposition of collagen in the tumor microenvironment
of both mouse and human CLC suggests that collagen pro-
duction is important for CLC development and progression.Figure 5. Metastatic Spectrum of mCLCs
(A and B) Representative H&E stainings revealing tumor cell invasion into surround
old Wcre;Cdh1F/F;PtenF/F mice (scale bars, 100 mm).
(C) Incidence of distant metastases inWcre;PtenF/+ (n = 15),Wcre;Cdh1F/F;PtenF/
depict different metastatic sites in metastasis-bearing Wcre;Cdh1F/F;PtenF/+ (n =
(D) Representative H&E stainings of tumor infiltration (marked by asterisks) in lym
(E) Representative FACS plots of GFP-sorted cells obtained from mammary
PtenF/F;mTmG mice, revealing dissemination of GFP-marked tumor cells to dista
(F) Fractions of Wcre;Cdh1F/F;PtenF/F;mTmG mice (n = 5) harboring GFP-markedCollagen has been implicated in the induction of tumor cell inva-
sion, as it was found to accumulate at invasive edges in breast
tumors (Egeblad et al., 2010; Provenzano et al., 2006) and to
induce in vitro invasion of cultured breast tumor cells (Nguyen-
Ngoc et al., 2012). Similarly, tumor cells in mCLCs align with
collagen as they invade the surrounding tissue. Both mouse
and human CLC showedmassive infiltration of fibroblasts, which
are, in general, the main source of collagen deposition. Future
studies will be required to investigate the importance of these
cancer-associated fibroblasts (CAFs) for mCLC development
and progression and whether targeting CAFs might provide a
useful strategy for treatment of human CLC.
In conclusion, in this study we presented concomitant inacti-
vation of E-cadherin and PTEN in mammary epithelium to drive
the formation of mCLC, thus developing a pertinent mouse
model for human CLC. This mouse model provides a powerful
in vivo tool to develop novel therapeutic strategies for CLC
patients, whichmay extend the relative limited treatment options
that are currently available in the clinic.EXPERIMENTAL PROCEDURES
Generation of Mice
We intercrossed Wcre;Cdh1F/F mice (Derksen et al., 2011, 2006) with PtenF/F
mice (Ma et al., 2005) and mTmG reporter mice (Muzumdar et al., 2007).
Mice were bred onto an FVB/N background and genotyped as described
previously (Derksen et al., 2006; Ma et al., 2005); (Muzumdar et al., 2007). All
animal experiments were approved by the Animal Ethical Committee and
were conducted in compliance with the Netherlands Cancer Institute and
Dutch Animal Welfare guidelines.
Isolation of Primary Mammary Epithelium for Organoid Generation
Purified primary mammary epithelial fragments were obtained from
isolated mammary glands by mechanical disruption, collagenase/trypsin
digestion, and differential centrifugation to generate organoids as previously
described (Ewald et al., 2008). For additional details, see the Supplemental
Information.
Immunoblotting, IF, and Histopathology
Immunoblotting, IF, and histopathological analysis was performed as
described in the Supplemental Information.
Mammary Gland Reconstitution
Mammary gland reconstitutions were performed based on previously
described mouse mammary epithelial cell transplantation (Evers et al.,
2010). In brief, the fourth mammary glands of 18- to 21-day-old wild-type or
mTmG mice on FVB/N background were cleared by surgical removal of
the epithelium-containing part, including the lymph node, and were engrafted
with small fragments (1-2 mm in diameter) of mammary gland tissue from 5- to
6-week-old Wcre;Cdh1F/F;PtenF/F mice. Transplanted mice were checked
biweekly for the development of tumors.ing muscular tissue (A) and nerve tissue (B) in mammary glands from 12-week-
+ (n = 32),Wcre;PtenF/F (n = 26), andWcre;Cdh1F/F;PtenF/F (n = 62) mice. Colors
11) and Wcre;Cdh1F/F;PtenF/F (n = 3) mice.
ph node, lung, pleura, peritoneum, and spleen. Scale bars, 200 mm.
tumors, blood, lungs, and bone marrow of tumor-bearing Wcre;Cdh1F/F;
nt organs.
tumor cells in indicated organs.
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Figure 6. Early Stromal Recruitment in Mouse and Human CLC
(A and B) In (A), H&E andMasson’s trichrome staining (revealing collagen) and IHC of PDGFRb (fibroblasts), CD3 (T cells), and F4/80 (macrophages) in tumor-free
mammary glands and mCLCs from wild-type, Wcre;Cdh1F/F, Wcre;PtenF/F, and Wcre;Cdh1F/F;PtenF/F mice of indicated age were used to examine stromal
compositions in each indicated genotype, which were subsequently compared to (B) the microenvironment of healthy human mammary glands and the tumor
microenvironment of human CLCs.
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Figure 7. Inhibition of PI3K Signaling Has Antitumor Activity inWcre;Cdh1F/F;PtenF/F Mice
(A) Representative IHC of p-AKT and p-S6, reflecting PI3K signaling activity in mCLCs from Wcre;Cdh1F/F;PtenF/F mice treated with either vehicle or BEZ235.
(B) Western blot analysis of p-AKT/AKT and p-S6/S6 expression, reflecting PI3K signaling activity in mCLCs from vehicle-treated and BEZ235-treated
Wcre;Cdh1F/F;PtenF/F mice.
(C) H&E staining of mammary glands from Wcre;Cdh1F/F;PtenF/F mice treated with vehicle or BEZ235. Lesions are indicated by arrows.
(D) Quantification of lesion formation by measuring total lesion area over total mammary gland tissue area for vehicle-treated (n = 6) and BEZ235-treated (n = 6)
Wcre;Cdh1F/F;PtenF/F littermates, compared to age-matched Wcre;Cdh1F/F;PtenF/F mice (n = 9) at start of treatment (t = 0).Genomic Analysis
RNA sequencing, whole-exome sequencing, andCNV analysis was performed
as described in the Supplemental Information.
Flow Cytometry
Blood samples were collected in tubes containing heparin. Tumors and lungs
were mechanically chopped using a McIlwain tissue chopper (Mickle Labora-tory Engineering), followed by digestion for 1 hr at 37C in 3mg/ml collagenase
type A (Roche) and 25 mg/ml DNase (Sigma-Aldrich) in serum-free DMEMme-
dium. Enzyme activity was neutralized by the addition of cold DMEM/10% fetal
bovine serum (FBS), and suspensions were dispersed through a 70-mm
cell strainer. Bone marrow was isolated through the flushing of two
femurs using PBS. All single-cell suspensions were treated with erythrocyte
lysis buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.5 M EDTA) and collected inCell Reports 16, 2087–2101, August 23, 2016 2099
PBS + 1% BSA. DAPI (1:20) was added to exclude dead cells. GFP-positive
cells were analyzed using a Beckman Coulter CyAn ADP flow cytometer and
FlowJo software.
BEZ235 Intervention Study
Eight-week-old littermates were orally dosed on a daily basis with 30 mg/kg
BEZ235 dissolved in 10% N-methyl-2-pyrrolidone/90% PEG 400 (polyeth-
ylene glycol 400) (Sigma-Aldrich) or vehicle for a period of 28 days. Two hours
after the last dosing, mice were sacrificed, and mammary glands were
harvested for further analysis. Antitumor activity was assessed by calculating
the ratio between the sumof all CLC regions and the total mammary gland area
using ImageJ.
Statistics
The following statistics were used for the indicated figures: for Figures 1C, 1E,
2D, S2C, and S2D, an unpaired t test was used; for Figures 3A and S3A, we
used a log-rank Mantel-Cox test; for Figure 3D, a Mann-Whitney test was
used; for Figure S3C, differential expression was assessed using limma
(Ritchie et al., 2015); and a one-tailed Mann-Whitney U test was used for Fig-
ure 4E. For Figure 7D, a paired t test was performed on these ratios between
BEZ235- and vehicle-treated littermates.
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